Metformin and rosiglitazone combination therapy is known to improve insulin resistance and postpone diabetes mellitus development in subjects with impaired glucose tolerance. This double-blind, randomized, controlled study assessed this combination therapy for preventing type 2 diabetes in obese subjects with hyperinsulinaemia. Subjects received metformin (500 mg three times daily, orally) plus either rosiglitazone (4 mg once daily, orally; n = 94) or placebo (n = 95) and were followed for 6 months. Blood pressure, body fat, body mass index (BMI), lipid and insulin levels were recorded pre-and post-treatment. Metformin plus rosiglitazone significantly decreased blood pressure, lipids, BMI, and fasting and postmeal insulin levels. Metformin plus placebo led to a significant decrease in blood pressure, BMI and lipid levels, but fasting and postmeal insulin levels were unchanged. Adverse events were similar between the two groups. The metformin and rosiglitazone combination increased insulin sensitivity and b-cell function recovered. This approach may represent a therapeutic option for preventing development of type 2 diabetes in obese subjects with hyperinsulinaemia.
Introduction
The incidence of type 2 diabetes mellitus is increasing worldwide, and the disease has become an economic as much as a health issue. 1 China has a population that exceeds one billion, which equates to 20% of the world's population; 2 by 2025, there could be over 20 million Chinese citizens with type 2 diabetes mellitus. 2, 3 The prevalence of type 2 diabetes is highly associated with the development of obesity, 4,5 and the major basis for the link between both conditions is insulin resistance. 6 Insulin resistance is a fundamental aspect of the aetiology of type 2 diabetes and is associated with a wide array of pathophysiological sequelae *X Li and N Zhang contributed equally to this paper. X Li, N Zhang, Y Li et al.
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including hypertension, hyperlipidaemia and atherosclerosis. 7 Interventions that aim to prevent diabetes in obese individuals are urgently required. 8 Presently, few safe and effective drugs for obesity management are available. Although previous research has shown that metformin can improve insulin resistance in obese people, 9 a small study showed that insulin sensitivity did not improve significantly in individuals who received metformin when compared with those given placebo. 10 Rosiglitazone has been shown to improve insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. 11, 12 By assessing insulin-sensitivity parameters, the aim of the present randomized, controlled trial was to clarify whether combination therapy with rosiglitazone and metformin could be beneficial for obese subjects.
Subjects and methods

SUBJECTS
Obese people who were referred to the Endocrine Clinic at Xijing Hospital, Xi'an, China between June 2006 and June 2008 were screened. Individuals with a body mass index (BMI) > 28 kg/m 2 and a waist/hip ratio > 0.9, according to the National Obesity Practice Guidelines of China 2003, 13 were eligible for inclusion in the study. Blood pressure, body weight, BMI, waist circumference, routine blood chemistry and an oral glucose tolerance test (OGTT) were measured at baseline. Key exclusion criteria were known type 1 or type 2 diabetes mellitus, infectious diseases, immune system diseases, tumour, medication history with possible influence on insulin sensitivity in the previous 6 months and contraindications to metformin or rosiglitazone therapy. Subjects with serious cardiovascular disease (e.g. New York Heart Association class I -IV congestive heart failure or a history of myocardial infarction or stroke) or cerebrovascular conditions within 6 months prior to study enrolment were excluded. Women who were pregnant or breastfeeding, or of childbearing age and not using adequate contraception, were also excluded.
All subjects received verbal and written information about the study before providing written consent. This study was approved by The Xijing Hospital Ethics Committee (Xi'an, China) and conducted in accordance with the Declaration of Helsinki and its amendments.
STUDY DESIGN, TREATMENT AND COMPLIANCE ASSESSMENT
Participants were randomly assigned to receive metformin plus rosiglitazone, or metformin plus placebo, for 6 months; the dosing schedule is described below. Randomization was performed by a computer-generated random number and metformin, rosiglitazone and placebo were dispensed by the pharmacy of Xijing Hospital. All participants and investigators were blinded to the intervention until after final data analysis.
All participants received standardized information on healthy eating and exercise. Metformin and rosiglitazone dosages were gradually increased over a 2-week period to final dosages of metformin orally 500 mg three times daily and rosiglitazone orally 4 mg once daily. Rosiglitazone and placebo were supplied as identical, opaque, white capsules in coded bottles, to ensure that the blinded status of the study was maintained.
Medication compliance was assessed by counting the number of pills returned at the time of specified clinic visits. Subjects were considered non-compliant if cumulative capsule consumption was < 75%. All medications were provided free of charge. Unused medication was retrieved for X Li, N Zhang, Y Li et al.
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inventory after study completion.
EFFICACY ASSESSMENTS
Initial laboratory assessments consisted of routine blood chemistry profiling, serum thyrotropin and glycosylated haemoglobin analyses and urinalysis, using standard laboratory methods. Venous blood samples (5 ml) were taken after an overnight (8 -10 h) fast at baseline and at 6 months posttreatment; a 2 ml blood sample was anticoagulated with ethylenediaminetetraacetic acid and stored at -20°C until further use; the remaining 3 ml were sent immediately to the clinical laboratory for biochemical marker testing.
The following parameters were assessed before the study and on its completion: liver function tests, which included assay of alanine transaminase (ALT), aspartate aminotransferase (AST) and γ-glutamyltransferase (γ-GT) levels; insulin and Cpeptide concentrations, analysed by radioimmunoassay using a double-antibody kit (ICN Pharmaceuticals, Costa Mesa, CA, USA); plasma glucose levels, determined by the glucose oxidase method; 14 glucosestimulated insulin response and insulin sensitivity, determined using the OGTTafter an overnight fast, a glucose bolus of 75 g was administered orally and insulin resistance was measured by the ratio of insulin to glucose and by the homeostatic model assessment of insulin resistance (HOMA-IR) index (HOMA-IR = fasting insulin [µIU/ml] × glucose [mmol/l]/22.5). 15 Total serum cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol and triglyceride concentrations were also measured before the study and on its completion, using standard enzymatic laboratory methods, and plasma free fatty acid levels were determined by high-performance liquid chromatography as described previously. 16 Fat composition was measured by bioelectrical impedance analysis using the Tanita TBF-300 bioresistance body composition analyser (Tanita, Tokyo, Japan), according to the manufacturer's instructions.
STATISTICAL ANALYSES
Statistical analyses were carried out using the SPSS ® statistical package, version 10.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Normally distributed data are reported as mean ± SD and non-parametric data as median (range). To assess the effect of metformin plus placebo versus metformin plus rosiglitazone, the paired sample t-test was used to compare means for normally distributed data and the Wilcoxon signedrank test was used to compare paired medians for non-parametric data. A P-value < 0.05 was considered to be statistically significant.
Results
SUBJECT CHARACTERISTICS
In total, 272 obese subjects aged 21 -45 years were referred for study inclusion; 57 did not meet the inclusion criteria and 14 refused to participate. Thus, 201 subjects were enrolled: 100 were randomized to the metformin plus placebo group and 101 to the metformin plus rosiglitazone group. Three subjects (3.0%) in the metformin plus rosiglitazone group and two (2.0%) in the metformin plus placebo group experienced mild adverse events (see below) which resulted in cessation of therapy; their symptoms disappeared within 1 week. Another three subjects (3.0%) in the metformin plus placebo group and four (4.0%) in the metformin plus rosiglitazone group dropped out during follow-up (six moved to another city and one lost contact). Thus, 94 subjects (93.1%) in the metformin X Li, N Zhang, Y Li et al.
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plus rosiglitazone group and 95 subjects (95.0%) in the metformin plus placebo group completed the 6-month treatment period. There were no significant between-group differences in baseline characteristics (Table  1) .
ANTHROPOMETRY AND BODY COMPOSITION
Compared with baseline levels, after 6 months' treatment with either metformin plus rosiglitazone or metformin plus placebo, significant beneficial effects on BMI, waist circumference, total body fat percentage and diastolic blood pressure were observed (P < 0.05, Table 1 ). Compared with metformin plus placebo, metformin plus rosiglitazone resulted in significant additional improvements in BMI, diastolic blood pressure and body fat percentage (P < 0.05, Table 1 ). Although statistically significant changes in hypertriglyceridaemia were not observed in this study, a significant reduction in free fatty acid levels compared with baseline levels was seen in both groups (P < 0.05): this reduction was further significantly improved in the metformin plus rosiglitazone group compared with the metformin plus placebo group (P < 0.05, Table 1 ). No variations in liver function parameters (ALT, AST and γ-GT) were observed in either group (data not shown).
INSULIN SENSITIVITY AND b-CELL FUNCTION
Compared with baseline levels, after 6 
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months of treatment with either metformin plus rosiglitazone or metformin plus placebo, significant beneficial effects on insulin and C-peptide levels and insulin sensitivity were seen; significant benefits on HOMA-IR were also observed in the metformin plus rosiglitazone group (P < 0.05, Fig. 1 ). In addition, a significant between-group difference was also observed, with the post-treatment effects being more pronounced in the metformin plus rosiglitazone compared with the metformin plus placebo group (P < 0.05).
ADVERSE EVENTS
Overall adverse event rates were similar in both study groups. The incidence of adverse events commonly associated with metformin 
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therapy, such as diarrhoea, nausea and abdominal discomfort, was similar between the two groups; such events were generally transient, disappearing within 2 weeks of starting therapy. Three of the 101 subjects (3.0%) originally enrolled into the metformin plus rosiglitazone group experienced mild diarrhoea and abdominal discomfort, which resulted in cessation of therapy. In the metformin plus placebo group, two of the 100 subjects (2.0%) originally enrolled experienced mild abdominal discomfort and refused to continue treatment; their symptoms disappeared within 1 week of cessation of therapy. Peripheral oedema occurred in four subjects (4/101; 4.0%) originally randomized to the metformin plus rosiglitazone group and in two subjects (2/100; 2.0%) originally randomized to the metformin plus placebo group. Only one subject (in the metformin plus rosiglitazone group) experienced hypoglycaemia ( Table 2) . No cardiovascular events were reported.
Discussion
The present study demonstrated that both metformin monotherapy and metformin plus rosiglitazone combination therapy have beneficial effects on weight, waist circumference, total body fat percentage, diastolic blood pressure, insulin and Cpeptide levels, and insulin sensitivity in normoglycaemic morbidly obese adults. The study population included subjects, 21 -45 years of age, who had been referred to the endocrine service for management of obesity and insulin resistance. Previous research demonstrated that, although metformin helped obese subjects to lose weight, levels of insulin sensitivity changed very little in patients on therapy. 9 Treatment effects in the present study were shown by the recovery of insulin sensitivity in both the metformin plus placebo and metformin plus rosiglitazone groups. This difference between the two studies might be explained by several factors. First, the inclusion criteria were different in the two studies. The present study involved obese Chinese adults who were less overweight than those from the study by Freemark and Bursey, 9 which included obese adolescent Americans; the present study included patients with a BMI > 28 kg/m 2 and waist/hip ratio > 0.9, which was lower than the criteria in the Freemark and Bursey study. 9 Secondly, there is evidence that people of Chinese origin are more likely to be 17 Thirdly, lifestyle factors vary greatly between different study populations. For example, the traditional Chinese diet is carbohydrate-based, whereas the Western diet is characterized by a higher lipid and protein intake. 18 In addition, walking and cycling are the most common methods of transportation in China, whereas motorized transport is widely used in Western countries; consequently, levels of physical exercise are higher in the Chinese population. 19 Finally, the different treatment regimens and study durations may have led to the different outcomes reported in the present and previous 9 studies.
Metformin has a beneficial effect on hyperglycaemia for overweight patients with type 2 diabetes, without causing hypoglycaemia and further weight gain. 20 By virtue of its insulin-sensitizing action, metformin appears to have promise in obese subjects as an effective weight-loss agent with a good safety profile; it reduces centripetal obesity and has the added bonus of reducing the chronic risk factors for heart diseaseincluding hyperinsulinaemia and high LDL cholesterol levels -that are present in obese subjects. 21 As an insulin sensitizer, rosiglitazone activates peroxisome proliferator-activated receptor-γ, an adipocyte transcription factor. This stimulates adipocytes to express enough adiponectin, which improves insulin-stimulated glucose disposal, and increases the action of insulin. 22 The beneficial effect of rosiglitazone has been demonstrated in patients with type 2 diabetes and impaired glucose tolerance. 23, 24 The present study demonstrated that combining rosiglitazone with metformin resulted in better control of body weight than metformin monotherapy, as well as improving β-cell function and improving serum insulin levels and insulin sensitivity. Diastolic blood pressure was also lowered, although the mechanism by which this occurred is unclear. It is possible that, with the improvement of insulin sensitivity and the reduction in free fatty acids, lipid production and smooth muscle cell proliferation were inhibited, thereby resulting in a beneficial effect on atherosclerosis.
In conclusion, we believe that the present study is the first controlled, randomized, double-blind clinical trial to report that combined treatment with metformin and rosiglitazone shows a beneficial effect in obese subjects by improving insulin resistance. The findings suggested that combination treatment is a possible therapeutic option for reducing the risk of type 2 diabetes from developing in obese individuals. This combination therapy can also decrease hypertension and hypertriglyceridaemia in obese subjects and may be useful in clinical practice. The present study involved a limited number of subjects, and a larger clinical trial will be necessary to address the safety and benefit issues of this combination regimen.
